TAEST1901

Main purpose: To study the safety and tolerability of TAEST1901 in the treatment of subjects with advanced liver cancer or other advanced tumors whose genotype is HLA-A*02:01 and whose tumor antigen AFP is positive. Secondary purpose: 1. To study the preliminary effectiveness of TAEST1901 in the treatment of subjects with advanced liver cancer or other advanced tumors whose genotype is HLA-A*02:01 and whose tumor antigen AFP is positive. 2. To study the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of TAEST1901 cells after reinfusion into the human body, and to observe their proliferation and persistence in the body, as well as their effects on human immunological activity. 3. To study the AFP expression in the subjects and the replication of lentivirus before and after TAEST1901 treatment.